Crosstalk between long non-coding RNAs and Wnt/β-catenin signalling in cancer

Gang Yang1, Tianyi Shen2, Xiaoming Yi2, Zhengyu Zhang2, Chaopeng Tang2, Longxin Wang2, Yulin Zhou2, Wenquan Zhou1,2

1Department of Urology, Jinling Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China
2Department of Urology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu Province, China

Abstract

Long non-coding RNAs (lncRNAs) are non-protein-coding transcripts in the human genome which perform crucial functions in diverse biological processes. The abnormal expression of some lncRNAs has been found in tumorigenesis, development and therapy resistance of cancers. They may act as oncogenes or tumour suppressors and can be used as diagnostic or prognostic markers, prompting their therapeutic potentials in cancer treatments. Studies have indicated that many lncRNAs are involved in the regulation of several signal pathways, including Wnt/β-catenin signalling pathway, which has been reported to play a significant role in regulating embryogenesis, cell proliferation and controlling tumour biology. Emerging evidences have suggested that lncRNAs can interact with several components of the Wnt/β-catenin signalling pathway to regulate the expression of Wnt target genes in cancer. Moreover, the expression of lncRNAs can also be influenced by the pathway. Nevertheless, Wnt/β-catenin signalling pathway-related lncRNAs and their interactions in cancer are not systematically analysed before. Considering these, this review emphasized the associations between lncRNAs and Wnt/β-catenin signalling pathway in cancer initiation, progression and their therapeutic influence. We also provided an overview on characteristics of lncRNAs and Wnt/β-catenin signalling pathway and discussed their functions in tumour biology. Finally, targeting lncRNAs or/and molecules associated with the Wnt/β-catenin signalling pathway may be a feasible therapeutic method in the future.

KEYWORDS

cancer, long non-coding RNA, Wnt/β-catenin signalling pathway

1 | INTRODUCTION

Cancer is a class of disease with the potential to proliferate continuously due to stepwise alterations at the genetic, epigenetic and cellular levels. It has become a great threat to human health. Though having been extensively studied, multidrug resistance (MDR) of tumour cells remains to be an obvious barrier of cancer treatments. Therefore, a better understanding of mechanisms in tumorigenesis, progression and drug resistance in cancer will be imperative for the development of efficient therapeutic strategies. Recently, more and more reports revealed that mutations within the non-coding genome have a close relationship with tumour biology.1
Results from the latest GENCODE have indicated that there are only approximately 2% of the human genome are protein-coding genes, whereas the vast majority of the human genome is made up of non-coding RNAs (ncRNAs).\(^2\) In the past decades, lots of ncRNAs have been found, such as ribosomal RNA (rRNA), transfer RNA (tRNA), small nuclear RNA (snRNA) and microRNA (miRNA) as well as long non-coding RNA (lncRNA). Aberrations within the non-coding genome are major decisive factors contributed to human diseases.\(^3\) Among these non-protein-coding transcripts, lncRNAs, defined as longer than 200 nucleotides with little or no protein-coding ability, have emerged as essential regulators in diverse biological processes.\(^4\) They can interplay with DNA, RNA and proteins to regulate the target gene expression. They can also influence several signalling pathways including Wnt/\(\beta\)-catenin signalling pathway, which is a common pathway involved in embryogenesis, development and homeoeostasis of tissues. Aberrant regulation of the pathway is associated with human diseases.\(^7,8\)

The comprehensive interrelationship of lncRNAs and Wnt/\(\beta\)-catenin signalling pathway has appeared as a significant tumorigenic signalling network in various cancers. In this review, we summarized some lncRNAs which are associated with Wnt/\(\beta\)-catenin signalling pathway to describe their interactions and underlying mechanisms in cancer formation, development and response to treatments.

### 2 CHARACTERISTICS OF LNCRNAS AND THEIR FUNCTIONS IN CANCER

LncRNAs represent a novel heterogeneous group of ncRNAs that usually exhibit cell-type-specific expression manner.\(^9\) The genomic locations of lncRNAs can be classified into intragenic, bidirectional and intergenic on the basis of their relationship to adjacent protein-coding transcripts.\(^10\) They are initially transcribed through pathways similar to that of protein-coding genes. And their transcription is mediated via RNA polymerase II.\(^11,12\) Evidences have already indicated that lncRNAs can regulate gene expression at the epigenetic, transcriptional and post-transcriptional levels.\(^13\) For example, IncRNA CCAT2, which is up-regulated in colorectal cancer (CRC), can enhance tumour invasion and metastasis by regulating c-Myc transcription and activate the Wnt signalling pathway.\(^14\) LncRNA CCAT1 can promote the progression of gastric carcinoma depending on the post-transcriptional activity of c-Myc.\(^15\)

Functionally, lncRNAs are not the “transcriptional junk” any more. They play an important role in normal cellular proliferation and differentiation.\(^16\) They are predominantly localized in the nucleus or cytoplasm, and their function is location-specific.\(^17\) In nucleus, lncRNAs are involved in chromatin remodelling, transcriptional regulation and RNA processing, while cytoplasmic lncRNAs can modulate mRNA stability, splicing or translation regulation, interact with special proteins and influence cellular signalling cascades.\(^18\) Studies have shown that dysregulated expression of lncRNAs leads to diverse human diseases.\(^19\)–\(^21\) At present, masses of lncRNAs are known to be associated with the initiation and progression of cancer. They can function as oncogenes or tumour suppresses.\(^22\) Many lncRNAs have a tissue and cancer type-specific expression pattern and have already been shown to be useful as diagnostic and prognostic markers.\(^23\)–\(^25\) More recently, emerging evidences have revealed an important role of lncRNAs in tumour drug resistance as well.\(^26\) These findings strongly suggest that they could become potential therapeutic targets in cancer treatments.

### 3 WNT/\(\beta\)-CATENIN SIGNALLING PATHWAY AND ITS ROLE IN CANCER

Wnt signalling pathway is an evolutionarily highly conserved pathway which controls critical biological processes including embryonic development, normal homeoestasis of adult tissues and cell fate.\(^27,28\) It mainly contains three diverse signalling pathways: Wnt/\(\beta\)-catenin signalling pathway (canonical pathway), Wnt/Ca\(^{2+}\) pathway and Wnt/planar cell polarity (PCP) pathway. Among them, Wnt/\(\beta\)-catenin signalling pathway (Wnt pathway for short) has obtained particular attentions due to its versatile functions in cells. In this section, we will provide an overview of the molecular mechanism of Wnt pathway.

The primary components of Wnt pathway are as follows: Wnt ligands, Frizzled receptors, LRPS/6 co-receptors (low density lipoprotein-receptor-related protein 5/6), Dsh (Dishevelled), \(\beta\)-catenin and TCF/LEF (T-cell factor/lymphoid enhancer factor) as well as one “degradation complex” composed of APC (adenomatous polyposis coli), axin (the scaffolding protein) and two kinases: CK1\(\alpha\) (casein kinase 1\(\alpha\)) and GSK-3\(\beta\) (glycogen synthase kinase 3\(\beta\)). Wnt ligand and \(\beta\)-catenin play a vital role in this pathway. In the absence of Wnt ligand, the signalling cascade is repressed. Cytoplasmic \(\beta\)-catenin is phosphorylated and kept in low levels via proteasome-mediated destruction, which is controlled by the “degradation complex”. As a result, the translocation into nucleus is inhibited. However, when Wnt ligand binding to receptors at the surface of target cells, a chain of events is initiated that disrupt the degradation complex via Dsh (Dishevelled) phosphorylation. Then \(\beta\)-catenin is separated from the destruction complex and results in the accumulation and stabilization of \(\beta\)-catenin in cytoplasm.\(^29,30\) Subsequently, \(\beta\)-catenin is imported into the nucleus where it can interact with the TCF/LEF family transcription factors and recruit transcriptional co-activators p300 and/or CBP (CREB-binding protein) as well as other components to transcribe a cloud of downstream target genes.\(^31\) Examples of which including c-Myc and cyclin D1.\(^32,33\) A simple outline of the components and the action model of Wnt pathway are presented in Figure 1.

Multiply dysfunctions and mutation of the pathway have suggested a strong connection with different kinds of human diseases including cancer.\(^34,35\) It is demonstrated that the component of Wnt pathway itself may act as oncogenes or tumour suppressor genes. For example, familial adenomatous polyposis (FAP) is related to the mutation of APC,\(^36\) which facilitates aberrant activation of the Wnt pathway and results in adenomatous lesions owing to enhanced cell
The dysregulation of β-catenin and APC has also been found in sporadic colon cancer and some other kinds of tumours. In addition, Wnt pathway could function as a significant anticancer target in cancer treatments.

4 | THE INTERACTIONS BETWEEN LncRNAS AND WNT/β-CATENIN SIGNALLING PATHWAY

The Wnt pathway has been recognized as a pivotal pathway participated in the regulation of cell proliferation, tumorigenesis and progression as well as chemoresistance in various cancers. Dysregulation of the multifunctional protein β-catenin, which is a crucial signalling effector in the pathway, contributes to aberrant activation of Wnt pathway. Accumulating evidence demonstrated that lncRNAs could regulate several signal pathways via interacting with specific proteins. More recently, numerous lncRNAs have been found to target key molecules associated with Wnt pathway and affect the accumulation of β-catenin. Then, modulating Wnt target genes expression and cancer cell functions. For example, lncRNA CCAT2 was found to promote breast tumour progression by influencing the activity of β-catenin, and thus, activating the Wnt pathway. These findings suggest that they may have close relationships with each other in cancer. Here, we enumerated some Wnt pathway-related lncRNAs to explore their reciprocities in tumorigenesis and progression, drug resistance and radiosensitivity of cancers (Table 1). Their probable regulatory network was depicted in a schematic diagram (Figure 2). We also provided a perspective that a better understanding of the interactions between Wnt pathways and these lncRNAs may devise efficient strategies against tumour treatments.

4.1 | LncRNAs and Wnt/β-catenin pathway in tumorigenesis and tumour progression

As is known to all, the ability to propagate continuously is one of the primary characters of cancer, and the process contains various changes in gene expression. Previously, studies into mechanisms of tumorigenesis mostly focused on protein-coding genes. Recently, lncRNAs, with no protein-coding ability, have been found to play widespread functions in regulating gene expression and other biological processes. Moreover, a great many of studies have suggested that lncRNAs are essential for the regulation of tumour biology, particularly leading to abnormal expression of target gene products that contribute to the initiation and progression of numerous human cancer. For example, Wu et al reported that HOX transcript antisense RNA (HOTAIR), which was found to be up-regulated in human renal carcinoma (RCC) cells, could act as an oncogenic lncRNA in promoting the proliferation and invasion of cells. Besides, the Wnt pathway is also regarded as a very significant pathway involved in tumorigenesis and progression. Studies revealed that dysregulation of the pathway was involved in different kinds of human tumours.
TABLE 1 Overview of wnt/β-catenin pathway-related lncRNAs in diverse human cancers and their relations

| lncRNA | Cancer Type                  | Associations with cancer                                                                 | Interactions with Wnt pathway | References       |
|--------|------------------------------|------------------------------------------------------------------------------------------|-------------------------------|------------------|
| CRNDE  | Renal cell carcinoma         | Promote cell proliferation                                                                | Activate                      | Shao et al 88    |
| HOTAIR | Esophageal squamous cell carcinoma | Poorer prognosis; promote migration and invasion of ESCC cells in vitro. | Activate                      | Ge et al 89      |
|        | Pancreatic ductal adenocarcinoma | Reduce the radiosensitivity of PDAC cells                                              | Activate                      | Jiang et al 75   |
| CASC11 | Colorectal cancer            | Promote cell proliferation and metastasis                                               | Activate                      | Zhang et al 78   |
| CCAL   | Colorectal cancer            | Oncogene promote proliferation, progression, invasion and migration; MDR                | Activate                      | Ma et al 56      |
| CCA11  | Breast cancer                | Oncogene                                                                                 | Activate                      | Cai et al 58     |
| UCA1   | Oral squamous cell carcinoma | Oncogene                                                                                 | Activate                      | Yang et al 90    |
|        | Bladder cancer               | Increase chemoresistance                                                                  | Activate                      | Fan et al 87     |
| HOTTIP | Osteosarcoma                 | Increase chemoresistance                                                                  | Activate                      | Li et al 71      |
| LncTCF7| Liver cancer stem cell       | Oncogene                                                                                 | Activate                      | Wang et al 85    |
| HNF1A-AS1 | Osteosarcoma              | Oncogene                                                                                 | Activate                      | Zhao et al 91    |
| CTD903 | Colorectal cancer            | Tumour suppressor inhibit cell invasion and migration                                     | Suppress                      | Yuan et al 92    |
| AK126698 | Non-small cell lung cancer cell | Inhibit the proliferation and migration; increase apoptosis                             | Suppress                      | Fu et al 86      |
| Meg3   | A549/DDP lung cancer cell    | Enhance chemosensitivity                                                                  | Suppress                      | Xia et al 70     |
| p21    | Colorectal cancer            | Enhance the sensitivity of radiotherapy                                                  | Suppress                      | Wang et al 76    |

As the functions of lncRNAs influence many signalling pathways involved in multiple cellular processes, they could also interact with Wnt pathway through several mechanisms in tumorigenesis and progression. Recently, Shao et al reported that lncRNA CRNDE is obviously over expressed in RCC cells and the heightened CRNDE could accelerate proliferation of RCC cells via activating Wnt pathway. They found that CRNDE could somehow modulate PI3K/Akt/GSK3β pathway, then the level of β-catenin in nucleus is elevated, which ultimately controls target gene expressions. However, the detailed mechanism remains to be expounded in further studies. In another example, Wang et al identified a long non-coding RNA, LncTCF7, which contributes to liver cancer stem cell self-renewal and tumour proliferation by activating Wnt signalling. Mechanism research has shown that LncTCF7 recruits the SWI/SNF complex to the promoter of TCF7 to modulate its expression, leading to activation of Wnt pathway. These evidences have indicated that the abnormal expression of Wnt pathway-related lncRNAs plays an important role in tumour biology and could act as oncogenes. There are also several lncRNAs function as tumour suppressors. Fu et al showed that a negative regulator lncRNA AK126698, which is remarkably decreased in non-small cell lung cancer (NSCLC) cells, can promote apoptosis and reduce the proliferation and migration of NSCLC cells by targeting Fzd8 to suppress the Wnt pathway. They found that excessive expression of AK126698 down-regulated Fzd8, which in turn greatly inhibited β-catenin expression. And this study suggests that targeting the AK126698/Fzd8 interaction or disturbing AK126698 expression could become novel strategies in the treatment of NSCLC.

In summary, lncRNAs activate or suppress the Wnt pathway by targeting diverse components associated with the Wnt signalling cascade to modulate downstream gene expression, revealing a strong interaction between them in tumour formation and progression.

4.2 LncRNAs and Wnt/β-catenin pathway in therapeutical resistance

Chemotherapy is one of the major treatment methods of tumours. Nevertheless, chemoresistance remains an obvious obstacle against satisfactory treatment outcomes. The mechanisms of tumour drug resistance mainly including DNA damage repair, drug efflux, mutations of drug targets and cancer cell apoptosis. Though have been widely investigated, yet they have not been fully understood. Therefore, identification of the underlining mechanisms is of very important to develop effective strategies against drug resistance. It has recently been presumed that drug resistance is associated with genetic and epigenetic factors. Several studies have confirmed a role for lncRNAs in regulating chemoresistance. A previous study demonstrated that lncRNA ARA may result in adriamycin resistance in cancer, by modulating numerous signalling pathways. Li et al suggested that lncRNA HOTTIP could contribute to gemicitabine resistance through regulating HOXA13 in pancreatic cancer. A novel long non-coding RNA lncARSR was found by Qu et al who reported that lncARSR could promote sunitinib resistance in renal cell carcinoma cells and may function as a predictor and a potential therapeutic target for sunitinib resistance. These evidences emphasized the rising significance of lncRNAs in tumour chemotherapy. Besides, a variety of signalling pathways have significant contributions to the development of drug resistance. For instance, the Wnt pathway can enhance expressions of resistance factors such as MDR-1 and surviving. Dysregulation of Wnt pathway is associated with increased chemoresistance in human
For example, Su et al. showed that the inhibition of secreted frizzled-related protein is associated with chemoresistance of ovarian cancer by regulating Wnt pathway. Considering the functions of lncRNAs and Wnt pathway in drug resistance, we then explored the underlying mechanisms and crosstalk between them in chemoresistance of cancer. As is shown, XIA et al. demonstrated that MEG3 can induce cell cycle arrest and increase apoptosis by the activation of p53 as well as the inhibition of β-catenin and survivin, which is a target gene of Wnt pathway, resulting in the suppression of Wnt pathway and enhancement of chemosensitivity in non-small cell lung cancer. Li et al. also indicated that up-regulated HOTTIP could initiate tumorigenesis and induce drug resistance via activating the Wnt pathway, which suggested that HOTTIP may be a potential therapeutic target in osteosarcoma.

Radiotherapy is also considered as a vital component of treatment in malignant tumours. But some of them are seriously resistant to it, and the mechanism remains largely unknown, which further contributes to the poor prognosis of patients. Nowadays, several studies have indicated that some lncRNAs can affect the sensitivity of radiotherapy for human cancer. Moreover, Wnt pathway could also enhance resistance to radiotherapy, and Wnt inhibitors may restore radiotherapy resistance. These suggest that lncRNAs may have interactions with Wnt pathway in radiotherapy of cancer. As is shown, Jiang et al. reported that the expression of HOTAIR was increased with time in pancreatic ductal adenocarcinoma (PDAC) cells after X-ray treatment. It could influence the radiosensitivity of PDAC cells via regulating the expression level of Wnt inhibitory factor-1 (WIF-1), which can further inhibit the activation of Wnt pathway.

**FIGURE 2** The schematic drawing showed possible regulatory network of Wnt/β-catenin pathway-related lncRNAs and their interactions in cancers. (A) lncRNAs which activate the Wnt pathway. (B) lncRNAs which suppress the Wnt pathway. Legend: colourized arrows indicate stimulation, colorized "T" indicates suppression, black vertical arrows indicate up- or down-regulation.
pathway. And the decline of HOTAIR could enhance the expression of WIF-1, which leads to the suppression of Wnt pathway. As a consequence, decreased the proliferation, promoted the apoptosis and enhanced the radiosensitivity of PDAC cells after radiation. In another report, Wang et al found that long intergenic non-coding RNA-p21 (lincRNA-p21) increases the sensitivity of radiotherapy for CRC through targeting Wnt pathway. In mechanism, the X-ray treatment up-regulates the expression of lincRNA-p21 which could directly inhibit the stability and/or translation of β-catenin. As a result, the activity of Wnt pathway is suppressed. Moreover, pro-apoptotic protein Noxa is elevated by lincRNA-p21. In the end, promoted cell apoptosis and enhanced the radiosensitivity for CRC.

Collectively, these studies have revealed a potent interrelationship between lncRNAs and Wnt pathway in drug resistance and in radiotherapy of various cancers. Based on these findings, it is expected that further researches are needed to clarify molecular mechanisms between lncRNAs and Wnt pathway, which may act as candidates to develop novel strategies to reverse the chemoresistance and increase radioresensitivity of cancer.

4.3 The clinical applications of lncRNAs and Wnt/β-catenin pathway

Detection of the specific biomarkers of tumour is one of effective methods for the early diagnosis of tumours. LncRNAs apparently exhibit a tissue-specific expression and can be measured non-invasively, raising the possibility that they may serve as promising biomarkers and therapeutic targets in cancer. Several studies have reported that recognition of particular lncRNAs as biomarkers may be useful in improving the diagnostic and prognosis prediction of tumours. For instance, the IncRNA HOTAIR has been demonstrated to be connected with the increased invasion and metastasis of breast cancer cells and could serve as a predictor of overall survival and progression-free survival. It thus may have potential clinical applications as a biomarker for breast cancer.

Zhang et al reported that lncRNA CASC11 overexpression in CRC was related to TNM-staging. It can activate Wnt pathway through targeting heterogeneous ribonucleoprotein K (hnRNP-K) to promote proliferation and metastasis of CRC cells. Besides, CASC11 may have the ability to become a potential diagnostic biomarker and a promising therapeutic target for CRC. Another typical clinical application example is lncRNA PCA3, which is highly expressed in prostate cancer, can be detected in urine samples of patients and has been demonstrated to have greater sensitivity and specificity for the early diagnosis of prostate cancer than the normally used prostate-specific antigen (PSA) blood test.

Considering the functions of lncRNAs in cancer, recently, emerging studies have indicated that biological therapies targeting these lncRNAs by the use of small interfering RNAs, ribozymes, antisense oligonucleotides, and by the small molecule inhibitors may be novel approaches to fight against cancer. For example, CCAL is an oncogenic IncRNA that promotes the tumorigenesis and progression of colorectal cancer (CRC) through activation of Wnt pathway. Over-expression of CCAL was related to poor survival and poor response to adjuvant chemotherapy. CCAL knockout inhibited CRC cell proliferation, migration and invasion and induced cell apoptosis in vitro and in vivo, which make it a potential therapeutic target for CRC. The IncRNA UCA1 is highly up-regulated and may be a reliable biomarker in bladder cancer. RNA interference-mediated down-regulation of UCA1 inhibited proliferation, migration and invasion of the bladder cancer cell, suggesting it can be a novel therapeutic target. Nevertheless, the clinical use of the therapy targeting these lncRNAs is still in its infancy, there are many obstructions need to be solved before the clinical popularization of the lncRNA-based treatments.

On the other hand, several crucial components of the Wnt pathway could act as potential biomarkers for cancer diagnosis or prognosis and have been recognized as innovative targets for cancer therapy. Arend RC et al found that niclosamide could increased cell apoptosis and reduce cellular proliferation via inhibiting the Wnt pathway. Targeting the Wnt pathway may become a novel strategy for the treatment of ovarian cancer. Currently, several antibodies and small molecular inhibitors have been investigated and are undergoing pre-clinical or clinical trials, such as OMP-18R5 (Anti Fzd7 antibody), OMP54F28 (Soluble Fzd decoy receptor), PRI-724 (Inhibitor of TCF-CBP interaction), which have been described by Zhan T in the 2016. However, to date, there are no suitable candidates available in clinic that specifically and efficiently targets this pathway, mainly because of noteworthy side effects. And more efforts are needed to precisely regulate the pathway before their clinical applications.

5 CONCLUSIONS AND PERSPECTIVE

LncRNAs are a class of non-protein-coding RNAs, which play important roles in diverse biological processes. Accumulating evidences have strongly confirmed that lncRNAs have close interactions with Wnt pathway in tumorigenesis, development and therapy resistance. As is shown, many Wnt pathway-related lncRNAs are aberrantly expressed in various cancers. They are useful as diagnostic indicators or prognosis prediction of tumours and can act as oncogenes or tumour suppressor genes. In mechanism, these lncRNAs can activate or suppress the Wnt pathway by targeting different molecules associated with the pathway. Such as Wnt ligands, Wnt inhibitors, receptors, β-catenin, components of the degradation complex and transcription factors as well as elements in other signalling pathways, subsequently, regulating the expression of Wnt target genes involved in cell multiplication, migration, tumorigenesis and therapy resistance. Meanwhile, the expression of lncRNAs can also be influenced by Wnt pathway. For example, a recent report demonstrated that c-Myc, a downstream gene of Wnt pathway, could combine with the promoter region of CASC11 and improve histone acetylation to increase CASC11 expression in CRC.

To summarize, the close interaction between lncRNAs and Wnt/β-catenin signalling pathway seems to play a significant role in tumorigenesis, progression and influencing the response of cancer cells to treatments. Potential therapies targeting lncRNAs or Wnt pathway have been mentioned in some documents. However, further studies about the underlying mechanisms are needed to
promote an efficient therapeutic strategy into a reality by targeting lncRNAs and/or Wnt pathway in cancer.

ACKNOWLEDGEMENT

This work was supported by the National Natural Science Foundation of China (Grant Nos. 81372742 and 81372741).

CONFLICT OF INTEREST

The authors declare that we have no conflict of interest.

ORCID

Gang Yang ID http://orcid.org/0000-0001-9708-6952

REFERENCES

1. Xu J, Liu S. Noncoding RNAs in cancer cell plasticity. Adv Exp Med Biol. 2016;927:173-189.
2. Harrow J, Frankish A, Gonzalez JM, et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 2012;22:1760-1774.
3. Zhou S, Treloar AE, Lupien M. Emergence of the noncoding cancer genome: a target of genetic and epigenetic alterations. Cancer Discov. 2016;6:1215-1229.
4. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861-874.
5. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15:7-21.
6. Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21:1253-1261.
7. Duchartre Y, Kim YM, Kahn M. The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol. 2016;99:141-149.
8. Teo JL, Kahn M. The Wnt signaling pathway in cellular proliferation and differentiation: a tale of two coactivators. Adv Drug Deliv Rev. 2010;62:1149-1155.
9. Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22:1775-1789.
10. Yang L, Froberg JE, Lee JT. Long non-coding RNAs: fresh perspectives into the RNA world. Trends Biochem Sci. 2014;39:35-43.
11. Ip JY, Nakagawa S. Long non-coding RNAs in nuclear bodies. Dev Growth Differ. 2012;54:44-54.
12. Clark MB, Mattick JS. Long noncoding RNAs in cell biology. Semin Cell Dev Biol. 2011;22:366-376.
13. Feng S, Yao J, Chen Y, et al. Expression and functional role of reprogramming-related long noncoding RNA (lncRNA-ROR) in glioma. J Mol Neurosci. 2015;56:623-630.
14. Ling H, Spizzo R, Atlasi Y, et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013;23:1446-1461.
15. Yang F, Xue X, Bi J, et al. Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma. J Cancer Res Clin Oncol. 2013;139:437-445.
16. Xiong XD, Ren X, Cai MY, et al. Long non-coding RNAs: an emerging powerhouse in the battle between life and death of tumor cells. Drug Resist Updat. 2016;26:28-42.
17. Beckedorff FC, Amaral MS, Deocesano-Pereira C. Long non-coding RNAs and their implications in cancer epigenetics. Biosci Rep. 2013;33:pii: e00061.
18. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152:1298-1307.
19. Li X, Wu Z, Fu X. Long noncoding RNAs: insights from biological features and functions to diseases. Med Res Rev. 2013;33:517-553.
20. Wang F, Ying HQ, He BS, et al. Upregulated IncRNA-UC1A contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget. 2015;6:7899-7917.
21. Kim T, Jeon YJ, Cui R, et al. Role of MYC-regulated long noncoding RNAs in cell cycle regulation and tumorigenesis. J Natl Cancer Inst. 2015;107:pii: dju505.
22. Martens-Uzunova ES, Böttcher R, Croce CM, et al. Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2014;65:1140-1151.
23. Smolle MA, Bullock MD, Ling H, et al. Long non-coding RNAs in endometrial carcinoma. Int J Mol Sci. 2015;16:26463-26472.
24. Gao J, Cao R, Mu H. Long non-coding RNA UCA1 may be a novel diagnostic and predictive biomarker in plasma for early gastric cancer. Int J Clin Exp Pathol. 2015;8:12936-12942.
25. Tantai J, Hu D, Yang Y, Geng J. Combined identification of long non-coding RNA XIST and HIF1A-AS1 in serum as an effective screening for non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8:7887-7895.
26. Majidinia M, Yousefi B. Long non-coding RNAs in cancer drug resistance development. DNA Repair (Amst). 2016;45:25-33.
27. Mi K, Yasuda SY. Wnt/beta-catenin signaling in embryonic stem cell self-renewal and somatic cell reprogramming. Stem Cell Rev. 2011;7:836-846.
28. Serio RN. Wnt of the two horizons: putting stem cell self-renewal and cell fate determination into context. Stem Cells Dev. 2014;23:1975-1990.
29. Saito-Diaz K, Chen TW, Wang X, et al. The way Wnt works: components and mechanism. Growth Factors. 2013;31:1-31.
30. Voronkov A, Krauss S. Wnt/beta-catenin signaling and small molecule inhibitors. Curr Pharm Des. 2013;19:634-664.
31. Sasaki-Hajji M, Wang X, Hahn WC. Genomic insights into WNT/beta-catenin signaling. Trends Pharmacol Sci. 2014;35:103-109.
32. Rennoll S. Regulation of MYC gene expression by aberrant Wnt/beta-catenin signaling in colorectal cancer. World J Biol Chem. 2015;6:290-300.
33. Ziegler S, Rohrs S, Tickenbrock L, et al. Novel target genes of the Wnt pathway and statistical insights into Wnt target promoter regulation. FEBS J. 2005;272:1600-1615.
34. Liu CC, Tsai CW, Deak F, et al. Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer’s disease. Neuron. 2014;84:63-77.
35. Monga SP. beta-Catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. Gastroenterology. 2015;148:1294-1310.
36. Kinzler KW, Nilbert MC, Su LK, et al. Identification of FAP locus components and mechanism. Trends Pharmacol Sci. 2014;35:103-109.
37. Rennoll S. Regulation of MYC gene expression by aberrant Wnt/beta-catenin signaling in colorectal cancer. World J Biol Chem. 2015;6:290-300.
38. Gupta A, Verma A, Mishra AK, et al. The wnt pathway: emerging anticancer strategies. Recent Pat Endocr Metab Immune Drug Discov. 2013;7:138-147.
39. Le PN, McDermott JD, Jimeno A. Targeting the wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28. Pharmacol Ther. 2015;146:1-11.
40. Stewart DJ. Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst. 2014;106:djt356.
63. Liu Z, Sun M, Lu K, et al. The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregulation of p21(WAF1/CIP1) expression. PLoS ONE. 2013;8:e77293.
64. Jiang M, Huang O, Xie Z, et al. A novel long non-coding RNA ARA: adriamycin resistance-associated. Biochem Pharmacol. 2014;87:254-283.
65. Li Z, Zhao X, Zhou Y, et al. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. J Transl Med. 2015;13:84.
66. Qu L, Ding J, Chen C, et al. Exosome-transmitted IncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell. 2016;29:653-668.
67. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res. 2010;16:3153-3162.
68. Gao Y, Liu Z, Zhang X, et al. Inhibition of cytoplasmic GSK-3beta increases cisplatin resistance through activation of Wnt/beta-catenin signaling in A549/DDP cells. Cancer Lett. 2013;336:231-239.
69. Su HY, Lai HC, Lin YW, et al. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer. 2010;127:555-567.
70. Xia Y, He Z, Liu B, et al. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/beta-catenin signaling pathway. Mol Med Rep. 2015;12:4530-4537.
71. Li Z, Zhao L. Overexpression of long non-coding RNA HOTTIP increases chemoresistance of osteosarcoma cell by activating the Wnt/beta-catenin pathway. Am J Transl Res. 2016;8:2385-2393.
72. Jing L, Yuan W, RuoFan D, et al. HOTAIR enhanced aggressive biological behaviors and induced radio-resistance via inhibiting p21 in cervical cancer. Tumour Biol. 2015;36:3611-3619.
73. Chen J, Shen Z, Zheng Y, et al. Radiotherapy induced Lewis lung cancer cell apoptosis via inactivating beta-catenin mediated by upregulated HOTAIR. Int J Clin Exp Pathol. 2015;8:7878-7886.
74. Ding M, Zhang E, He R. Newly developed strategies for improving sensitivity to radiation by targeting signal pathways in cancer therapy. Cancer Sci. 2013;104:1401-1410.
75. Jiang Y, Li Z, Zheng S, et al. The long non-coding RNA HOTAIR affects the radiosensitivity of pancreatic ductal adenocarcinoma by regulating the expression of Wnt inhibitory factor 1. Tumour Biol. 2016;37:3957-3967.
76. Wang G, Li Z, Zhao Q, et al. LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/beta-catenin signaling pathway. Oncol Rep. 2014;31:1839-1845.
77. Shi T, Gao G, Cao Y. Long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer. Tumour Biol. 2015;36:3611-3619.
78. Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071-1076.
79. Zhang Z, Zhou C, Chang Y, et al. Long non-coding RNA CASC11 interacts with hnRNP-K and activates the WNT/beta-catenin pathway to promote growth and metastasis in colorectal cancer. Cancer Lett. 2016;376:62-73.
80. Lee GL, Dobi A, Srivastava S. Prostate cancer: diagnostic performance of the PCA3 urine test. Nat Rev Urol. 2011;8:123-124.
81. Mouraviev V, Lee B, Patel V, et al. Clinical prospects of long non-coding RNAs as novel biomarkers and therapeutic targets in prostate cancer. Prostate Cancer Prostatic Dis. 2016;19:14-20.
82. Parasramka MA, Maji S, Matsuda A, et al. Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma. Pharmacol Ther. 2016;161:67-78.
83. Wang Y, Chen W, Yang C, et al. Long non-coding RNA UCA1a (CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol. 2012;41:276-284.
84. Arend RC, Londoño-Joshi AI, Samant RS, et al. Inhibition of Wnt/beta-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. Gynecol Oncol. 2014;134:112-120.
85. Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2016;35:1461-1473.

86. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43:904-914.

87. Perry RB, Ulitsky I. The functions of long noncoding RNAs in development and stem cells. Development. 2016;143:3882-3894.

88. Shao K, Shi T, Yang Y, et al. Highly expressed IncRNA CRNDE promotes cell proliferation through Wnt/β-catenin signaling in renal cell carcinoma. Tumour Biol. 2016;37:15997-16004.

89. Ge XS, Ma HJ, Zheng XH, et al. HOTAIR, a prognostic factor in esophageal squamous cell carcinoma, inhibits WIF-1 expression and activates Wnt pathway. Cancer Sci. 2013;104:1675-1682.

90. Yang YT, Wang YF, Lai JY, et al. Long non-coding RNA UCA1 contributes to the progression of oral squamous cell carcinoma by regulating the WNT/β-catenin signaling pathway. Cancer Sci. 2016;107:1581-1589.

91. Zhao H, Hou W, Tao J, et al. Upregulation of IncRNA HNF1A-AS1 promotes cell proliferation and metastasis in osteosarcoma through activation of the Wnt/β-catenin signaling pathway. Am J Transl Res. 2016;8:3503-3512.

92. Yuan Z, Yu X, Ni B, et al. Overexpression of long non-coding RNA-CTD903 inhibits colorectal cancer invasion and migration by repressing Wnt/β-catenin signaling and predicts favorable prognosis. Int J Oncol. 2016;48:2675-2685.

How to cite this article: Yang G, Shen T, Yi X, et al. Crosstalk between long non-coding RNAs and Wnt/β-catenin signalling in cancer. J Cell Mol Med. 2018;22:2062–2070. https://doi.org/10.1111/jcmm.13522